髄芽腫に対する頭蓋脊髄放射線照射を受けた小児の脳修復のためのメトホルミン
髄芽腫に対する頭蓋脊髄放射線照射を受けた小児の脳修復を目的としたメトホルミンのプラセボ対照二重盲検クロスオーバー試験
A placebo controlled double blind crossover trial of metformin in 30 children treated with radiation for medulloblastoma - the most common malignant brain tumour. The investigators used tests of thinking and learning and brain imaging techniques to examine whether metformin can enhance cognition or promote brain repair following radiation-induced brain injury.
調査の概要
詳細な説明
We conducted a pilot randomized, double-blind, placebo-controlled trial with crossover in survivors of pediatric brain tumors with primary endpoints of safety and feasibility and secondary endpoints of cognitive and magnetic resonance imaging (MRI) measures. Twenty-four participants were enrolled and randomly assigned to complete 12-week cycles of metformin (A) and placebo (B) in either a group AB (AB) or group BA (BA) sequence. At the point of crossover, there was a 10-week washout period in which neither group received any treatment. During the first week of each treatment cycle, a daily dose of 500 mg/m2 of metformin or placebo was administered orally. The dose was increased to 1000mg/m2 daily beginning in the second week and continuing for the remainder of the 12-week cycle.
Test procedures (Clinical & current medications reviews, Blood draws, and MRI and Cognitive testing) were performed at 4 times points during the study: 1. at study entry (Baseline 1), 2. after 12 weeks of treatment (Outcome 1), 3. after a 10-week washout period at 22 weeks (Baseline 2), and 4. At the end of the trial at 34 weeks (Outcome 2).
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 1X8
- The Hospital for Sick Children
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria: Survivors will be included if they:
-
Have been treated with cranial or cranial-spinal radiation,
-
Are between 5 and 21 years of age at time of consent, and
-
Either declare English as their native language or have had at least two years of schooling in English at the time of their baseline assessment.
-
Have been diagnosed with a brain tumour requiring treatment with cranial or cranial-spinal radiation at least 2 years ago, is not receiving active treatment and no more than 15 years may have elapsed between treatment with cranial-spinal radiation and time of the trial. Survivors with a shunt will be included in the trial, but will need to be identified prior to study enrollment to discuss any specific considerations for imaging.
-
Meet criteria for adequate organ function requirements:
-
Adequate renal function defined as: Creatinine clearance or radioisotope glomerular filtration rate (GFR) > 70ml/min/1.73 m2 or serum creatinine based on age/gender as follows:
Maximum Serum Creatinine Level (mg/dL)
5 to < 10 years: Male = 1; Female = 1
10 to < 13 years: Male = 1.2; Female = 1.2
13 to < 16 years: Male = 1.5; Female = 1.4
≥ 16 years: Male = 1.7; Female = 1.4
-
Adequate liver function defined as:
Total bilirubin < 1.5 x upper limit of normal (ULN) for age, and,
serum glutamate oxaloacetate transaminase (SGOT) (AST) or serum glutamate pyruvate transaminase (SGPT) (ALT) < 3 x upper limit of normal (ULN) for age.
-
-
Females of childbearing potential must have a negative pregnancy test result and must agree to use a medically acceptable method of contraception throughout the entire study period and for 30 days after the last dose of study drug.
-
Informed consent will be obtained from the participants and/or their legal guardians by study team members authorized to consent for this study.
Exclusion criteria: Survivors will be excluded if they
- Are receiving palliative care.
- Are unable to participate in neuro-imaging without sedation as this is the primary outcome measure for the trial.
- Are unable to swallow tablets.
- Are unstable and/or insulin-dependent (Type 1) diabetic patients.
- Have acute or chronic metabolic acidosis and/or lactic acidosis.
- Any female patient or partner who has reached menarche and male patients who are not willing to use an effective method of contraception.
- Patient who is pregnant or lactating and does not agree to stop breastfeeding while receiving trial treatment.
- Have a history of renal disease or renal dysfunction e.g., as suggested by elevated serum creatinine levels (see 5.a. Inclusion criteria) or abnormal creatinine clearance.
- Have a history of congestive heart failure requiring pharmacologic treatment.
- Have a known hypersensitivity to metformin hydrochloride.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Group A (Crossover Group 1)
Subjects assigned to this arm will receive metformin first, followed by a washout period and then placebo. |
Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID. Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID. |
|
実験的:Group B (Crossover Group 2)
Subjects assigned to this arm will receive placebo first, followed by a washout period and then metformin. |
Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID. Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Feasibility: Medication Adherence
時間枠:Outcome 2 (Week 35)
|
Participant's adherence to taking study medication (Metformin or Placebo) as instructed based on dosing nomogram, for the whole study. % Medication adherence = (Number of tablets actually consumed / Number of tablets expected to be consumed)*100 Number of tablets actually consumed is based on compliance counts conducted at the end of the study. |
Outcome 2 (Week 35)
|
|
Safety: Frequency of Adverse Events (AE)
時間枠:Outcome 2 (Week 35)
|
The frequency of all AEs experienced during metformin and placebo treatment for all participants. |
Outcome 2 (Week 35)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cognitive Testing: Declarative Memory - Change in Children's Auditory Verbal Learning Test -2 (CAVLT-2)
時間枠:Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
|
For Arm AB:
For Arm BA:
|
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
|
|
Cognitive Testing: Working Memory - Change in List Sort Working Memory Subtest of the NIH Toolbox Cognition Battery
時間枠:Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), Outcome 2 (Week 35)
|
For Arm AB:
For Arm BA:
|
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), Outcome 2 (Week 35)
|
|
Cognitive Testing: Processing Speed - Change in Mean Reaction Time across Cambridge Neuropsychological Test Automated Battery (CANTAB) subtests
時間枠:Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
|
Change in Mean Reaction Time (MRT) across the following CANTAB subtests:
Each subtest provides an outcome measure of response latency, which will be averaged across all correct trials for each subtest to provide an overall measure of processing speed. For Arm AB:
For Arm BA:
|
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Neuroimaging: MRI Measures of White Matter Growth within the Corpus Callosum
時間枠:Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
|
Change in Axonal Water Fraction (AWF)- Diffusion Kurtosis Imaging (DKI) metric sensitive to myelin |
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
|
|
Neuroimaging: MRI Measures of Hippocampal Volume
時間枠:Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35
|
Change in Hippocampal Volume, as measured by Cerebral Blood Flow (CBF) |
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35
|
協力者と研究者
捜査官
- 主任研究者:Donald Mabbott, PhD、The Hospital for Sick Children
出版物と役立つリンク
一般刊行物
- Ayoub R, Ruddy RM, Cox E, Oyefiade A, Derkach D, Laughlin S, Ades-Aron B, Shirzadi Z, Fieremans E, MacIntosh BJ, de Medeiros CB, Skocic J, Bouffet E, Miller FD, Morshead CM, Mabbott DJ. Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin. Nat Med. 2020 Aug;26(8):1285-1294. doi: 10.1038/s41591-020-0985-2. Epub 2020 Jul 27.
- Baudou E, Ryan JL, Tseng J, Bouffet E, Bartels U, Timmons BW, de Medeiros CB, Mabbott DJ. Repairing Myelin After Irradiated Pediatric Brain Tumor: A Magnetization Transfer Imaging Analysis. Pediatr Blood Cancer. 2025 Sep;72(9):e31838. doi: 10.1002/pbc.31838. Epub 2025 Jun 14.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 1000039383
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。